modelDeferiprone

Extends from Pharmacolibrary.Drugs.ATC.V.V03AC02.

Information

name:Deferiprone
ATC code:V03AC02
route:oral
compartments:1
dosage:25mg
volume of distribution:1.6L
clearance:0.16L/h/kg
other parameters in model implementation

Deferiprone is an oral iron chelator primarily used for the treatment of iron overload in patients with thalassemia major and other chronic anemias, especially when standard chelation therapy is inadequate or contraindicated. It is approved and in use for this indication.

Pharmacokinetics

Pharmacokinetic parameters reported from studies in adult patients (both sexes) with thalassemia major receiving oral deferiprone under steady-state conditions.

References

  1. Bellanti, F, et al., & Della Pasqua, O (2014). Population pharmacokinetics of deferiprone in healthy subjects. British journal of clinical pharmacology 78(6) 1397–1406. DOI:10.1111/bcp.12473 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25052529

  2. Soulières, D, et al., & Tricta, F (2022). The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease. Annals of hematology 101(3) 533–539. DOI:10.1007/s00277-021-04728-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34981144

  3. Bellanti, F, et al., & Della Pasqua, O (2016). Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β-Thalassemia. Journal of clinical pharmacology 56(9) 1094–1103. DOI:10.1002/jcph.708 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26785826

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)